CO.DON AG: First Spherox transplantation successfully performed in Great Britain

DGAP-News: CO.DON AG / Key word(s): Expansion

09.05.2018 / 09:59

The issuer is solely responsible for the content of this announcement.


First Spherox transplantation successfully performed in Great Britain

Berlin / Teltow, 9 Mai 2018 – At the Royal Orthopaedic Hospital (ROH), Birmingham, one of the leading British orthopaedic centres, the first patient in Great Britain was treated with the autologous cartilage repair product Spherox. Last week, Professor Martyn Snow, Consultant Orthopaedic Surgeon at the ROH, transplanted the EU-wide authorized product. The 31-year-old patient injured his knee during sport six years ago.

Professor Snow explained that there are limited options available for treating cartilage defects larger than 2 cm2 and that the ROH is very pleased to have this new treatment option and to be the first hospital in the UK to use it. The body’s own cell therapy product could help many patients who are qualified for the treatment.

The British National Institute for Health and Care Excellence (NICE) estimates that each year around 10,000 people in the UK are diagnosed with cartilage damage that falls under the indication of the cell therapy product offered by CO.DON. While smaller injuries can be treated successfully with other methods, those with mid- to larger injuries to their cartilage would benefit from this novel treatment.

CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage defects in the knee following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). The treatment has been used in over 200 clinics to treat more than 12,000 patients. In July 2017 the company received EU marketing authorisation for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.
Further information is available from: www.codon.eu

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de


09.05.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this